UnitedHealth Group named Bain Capital executive Wayne DeVeydt its next chief financial officer, starting Sept. 2 https://t.co/1ktt6uz1h1 ...

Core Insights - Bristol Myers (BMY) has partnered with Bain Capital to establish a new independent biopharmaceutical company focused on developing therapies for autoimmune diseases, addressing significant unmet patient needs [1][9] - Bain Capital will invest $300 million in the new company, while BMY will out-license five immunology candidates and retain a nearly 20% equity stake [1][3][9] Summary by Categories Company Developments - The new company will focus on autoimmune disease therapies, with BMY out-licensing five immunology candidates, including three clinical stage candidates and two phase I-ready candidates [2][3] - The most advanced assets include afimetoran, an oral TLR7/8 inhibitor in phase II for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor with positive phase II results for plaque psoriasis [2] Financial Aspects - BMY will earn royalties and milestones based on the success of each asset in the new company [3][9] - BMY's shares have decreased by 17.2% year-to-date, contrasting with the industry growth of 0.6% [7][8] - BMY is trading at a price/earnings ratio of 7.59x forward earnings, lower than its historical mean of 8.51x and the large-cap pharma industry's 15.11x [10] Market Competition - BMY faces competition in the immunology space, particularly with its drug Sotyktu competing against Amgen's Otezla in psoriasis [5] - In oncology, BMY competes with major players like Merck, whose Keytruda dominates the immuno-oncology market [6] Future Estimates - The bottom-line estimate for 2025 has been revised down to $6.33 from $6.76 over the past month, with a slight decline in the 2026 estimate as well [11]

Core Insights - The Questex Resort & Residential Hospitality Forum (R&R Forum) is set to take place in Athens, Greece, from November 11-13, 2025, marking its 10th anniversary and expecting over 500 industry leaders and professionals [1][11] - The 2025 theme, "Powering Return on Experience," emphasizes the shift towards immersive and lifestyle-driven hospitality investments, reflecting changing consumer preferences [2][3] Industry Trends - There is a fundamental shift in customer trends where experiences are prioritized over material goods, particularly among younger generations, indicating sustained demand in the hospitality sector [3] - Lifestyle-led assets such as branded residences and mixed-use developments are gaining traction, providing stronger guest appeal and long-term returns while addressing seasonality challenges [3] Event Details - The 2025 program includes discussions on investment dynamics, market evolution, and performance strategies, featuring prominent speakers from various sectors [4][9] - Notable speakers include Gonzalo Aguilar from Minor Hotels and Sergio Carrascosa from Hotel Investment Partners, who will share insights on growth strategies and risk management in leisure hospitality [5][4] Networking Opportunities - The event will facilitate targeted networking through AI-driven matchmaking sessions and curated roundtables, aimed at fostering meaningful connections among participants [8][7] - Interactive sessions will allow attendees to engage directly with industry leaders, enhancing the collaborative environment [10] Historical Context - The R&R Forum celebrates a decade of influence in the leisure and resort sector, highlighting the evolution of travel trends and institutional interest in innovative hospitality models [11]

Bain Capital is already scouting for its next airline after more than tripling its money on the Virgin Australia IPO. Read today's Australia Briefing by @AngusWhitley1 for your daily dose of the best of Bloomberg from Down Under and around the world. https://t.co/92FfxKghZU ...

Bain Capital is scouting for its next airline deal after already more than tripling its money on Virgin Australia https://t.co/c7bFqt8Sx0 ...

Investment Activity - Bain Capital agreed to invest in PCI Pharma Services [1] Industry Focus - PCI Pharma Services is a drug services provider that helps assemble and package medicines [1]

Exclusive: Bain Capital and Kohlberg are leading an investment valuing biotech firm PCI Pharma at $10 billion including debt https://t.co/3GERxnWOIJ ...

Canada Goose’s controlling shareholder Bain Capital is considering a sale of its stake in the luxury parka-maker https://t.co/GtVG4YqVTP ...

Warner Music and Bain Capital are joining together to invest as much as $1.2 billion in iconic music catalogs. https://t.co/B0CMZR0deh ...

Core Insights - Warner Music Group (WMG) and Bain Capital are launching a joint venture to acquire up to $1.2 billion in music catalogs, encompassing both recorded music and music publishing [1][2] - The partnership aims to provide artists and songwriters with opportunities to preserve and expand their catalogs, ensuring their legacies are well managed [2][4] - The deal is timely for the music industry, as changing fan behavior driven by streaming and technology is introducing classic music to new audiences [3] Company Overview - Warner Music Group operates in over 70 countries and includes renowned labels and a music publishing arm with over one million copyrights across various genres [6] - Bain Capital, founded in 1984, is a leading private investment firm with approximately $185 billion in assets under management and a commitment to creating lasting impact [7] Strategic Implications - The joint venture combines WMG's global infrastructure and relationships with Bain Capital's financial resources, positioning it as a preferred partner for iconic musical talent [2][4] - The collaboration emphasizes the importance of catalog stewardship, aiming to enhance the value of artists' work while delivering new collaborations to fans [4] Financial Arrangements - Goldman Sachs and Fifth Third Bank will serve as joint lead arrangers for the joint venture [4]